{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:13:44Z","timestamp":1794935624425,"version":"4.9.1"},"reference-count":128,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2021.01.055","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T16:46:16Z","timestamp":1614098776000},"page":"3053-3066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7689","authenticated-orcid":false,"given":"Flor M.","family":"Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob P.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia L.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Z.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando P.","family":"Polack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-5353","authenticated-orcid":false,"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Van Braeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud M.","family":"Didierlaurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Henri","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6494","key":"10.1016\/j.vaccine.2021.01.055_b0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science (New York, NY)"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin Vaccine Immunol: CVI"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/14760584.2016.1115353","article-title":"Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis","volume":"15","author":"Jorquera","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0020","doi-asserted-by":"crossref","first-page":"566","DOI":"10.23736\/S0026-4946.18.05305-7","article-title":"Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives","volume":"70","author":"Vittucci","year":"2018","journal-title":"Minerva Pediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/08828240152716556","article-title":"Immune responses to measles and measles vaccine: challenges for measles control","volume":"14","author":"Moss","year":"2001","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0030","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2741\/2767","article-title":"Measles vaccines","volume":"13","author":"Griffin","year":"2008","journal-title":"Front Biosci: J Virtual Library"},{"issue":"10169","key":"10.1016\/j.vaccine.2021.01.055_b0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Wilder-Smith","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2017.1254550","article-title":"The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis","volume":"15","author":"Gan","year":"2017","journal-title":"Expert Rev Anti-Infective Therapy"},{"issue":"14","key":"10.1016\/j.vaccine.2021.01.055_b0045","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2016.02.004","article-title":"Protective and immunological behavior of chimeric yellow fever dengue vaccine","volume":"34","author":"Halstead","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1586\/14760584.2016.1116949","article-title":"Immune correlates for dengue vaccine development","volume":"15","author":"Srikiatkhachorn","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfma.2012.11.006","article-title":"Autoimmunity in dengue pathogenesis","volume":"112","author":"Wan","year":"2013","journal-title":"J Formosan Med Assoc = Taiwan yi zhi"},{"key":"10.1016\/j.vaccine.2021.01.055_b0060","series-title":"Influenza Pathogenesis and Control \u2013 Volume 1. Current Topics in Microbiology and Immunology","first-page":"315","article-title":"Pathogenesis and Vaccination of Influenza A Virus in Swine","author":"Rajao","year":"2014"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0065","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New England J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0070","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Human Vaccines Immunotherap"},{"key":"10.1016\/j.vaccine.2021.01.055_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0080","doi-asserted-by":"crossref","DOI":"10.3201\/eid2609.202095","article-title":"Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States","volume":"26","author":"Martines","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respiratory Med"},{"key":"10.1016\/j.vaccine.2021.01.055_b0090","unstructured":"The Royal College of Paediatrics and Child Health. Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS); 2020 [Available from: https:\/\/www.rcpch.ac.uk\/resources\/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims]."},{"issue":"10237","key":"10.1016\/j.vaccine.2021.01.055_b0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"Riphagen","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"10239","key":"10.1016\/j.vaccine.2021.01.055_b0100","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2021.01.055_b0105","unstructured":"Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19); 2020 [updated March 27, 2020. Available from: https:\/\/emergency.cdc.gov\/han\/2020\/han00432.asp."},{"issue":"31","key":"10.1016\/j.vaccine.2021.01.055_b0110","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2020.05.064","article-title":"Consensus summary report for CEPI\/BC March 12\u201313, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines","volume":"38","author":"Lambert","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0115","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0120","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.055_b0145","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/jvi.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells","volume":"66","author":"Connors","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0150","doi-asserted-by":"crossref","first-page":"34108","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.vaccine.2021.01.055_b0155","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2006.03.064","article-title":"The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease","volume":"24","author":"Boukhvalova","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004757","article-title":"RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets","volume":"11","author":"Knudson","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.01.055_b0165","doi-asserted-by":"crossref","unstructured":"Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol (Baltimore, Md: 1950) 2008;180(4):2376\u201384.","DOI":"10.4049\/jimmunol.180.4.2376"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/CMR.18.3.541-555.2005","article-title":"Immune responses and disease enhancement during respiratory syncytial virus infection","volume":"18","author":"Openshaw","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.01.055_b0175","doi-asserted-by":"crossref","unstructured":"Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (Baltimore, Md: 1950) 1993;151(4):2032\u201340.","DOI":"10.4049\/jimmunol.151.4.2032"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0180","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2021.01.055_b0185","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1128\/JVI.01347-13","article-title":"The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection","volume":"87","author":"Stokes","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0190","doi-asserted-by":"crossref","unstructured":"Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, Miyahara N, et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol (Baltimore, Md: 1950) 2005;175(3):1876-83.","DOI":"10.4049\/jimmunol.175.3.1876"},{"key":"10.1016\/j.vaccine.2021.01.055_b0195","first-page":"3","article-title":"Enders and measles virus vaccine\u2013a reminiscence","volume":"329","author":"Katz","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1056\/NEJM196007282630408","article-title":"Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine","volume":"263","author":"Katz","year":"1960","journal-title":"New England J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/inf.1970.2.issue-3.02","article-title":"Atypical measles after vaccination with killed vaccine","volume":"2","author":"R\u00f8d","year":"1970","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.055_b0210","doi-asserted-by":"crossref","unstructured":"Young LW, Smith DI, Glasgow LA. Pneumonia of atypical measles. Residual nodular lesions. Am J Roentgenol, Radium Therapy, Nucl Med 1970;110(3):439-48.","DOI":"10.2214\/ajr.110.3.439"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/9473","article-title":"Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody","volume":"5","author":"Polack","year":"1999","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0220","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm918","article-title":"A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles","volume":"9","author":"Polack","year":"2003","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0225","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/77506","article-title":"Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles","volume":"6","author":"Polack","year":"2000","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.055_b0230","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1128\/JVI.75.10.4499-4505.2001","article-title":"CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition","volume":"75","author":"Erlenhoefer","year":"2001","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-3476(78)80889-0","article-title":"Revaccination of previous recipients of killed measles vaccine: clinical and immunologic studies","volume":"93","author":"Krause","year":"1978","journal-title":"J Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0240","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nm1456","article-title":"A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines","volume":"12","author":"Moghaddam","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0245","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1073\/pnas.1217580110","article-title":"Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells","volume":"110","author":"Loebbermann","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.186.3.421","article-title":"Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection","volume":"186","author":"Srikiatkhachorn","year":"1997","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.055_b0255","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/eji.1830271233","article-title":"CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection","volume":"27","author":"Hussell","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0260","doi-asserted-by":"crossref","unstructured":"Castilow EM, Legge KL, Varga SM. Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol (Baltimore, Md: 1950) 2008;181(10):6692-6.","DOI":"10.4049\/jimmunol.181.10.6692"},{"issue":"4839","key":"10.1016\/j.vaccine.2021.01.055_b0265","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.239.4839.476","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.146.1.201","article-title":"Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody","volume":"146","author":"Halstead","year":"1977","journal-title":"J Exp Med"},{"issue":"6365","key":"10.1016\/j.vaccine.2021.01.055_b0275","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science (New York, NY)"},{"issue":"13","key":"10.1016\/j.vaccine.2021.01.055_b0280","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New England J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0285","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"New England J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2021.01.055_b0290","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14712598.2018.1526277","article-title":"Rapid travel to a Zika vaccine: are we heading towards success or more questions?","volume":"18","author":"Britto","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"suppl_10","key":"10.1016\/j.vaccine.2021.01.055_b0295","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1093\/infdis\/jix513","article-title":"Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity","volume":"216","author":"Priyamvada","year":"2017","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0300","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00055-16","article-title":"The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiology and molecular biology reviews","volume":"81","author":"Heinz","year":"2017","journal-title":"MMBR"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jmv.20255","article-title":"An interferon-gamma-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2005.07.007","article-title":"A probable role for IFN-gamma in the development of a lung immunopathology in SARS","volume":"32","author":"Theron","year":"2005","journal-title":"Cytokine"},{"issue":"16","key":"10.1016\/j.vaccine.2021.01.055_b0315","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1128\/JVI.00527-07","article-title":"Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome","volume":"81","author":"Cameron","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0325","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1164\/rccm.200407-857OC","article-title":"Characterization of cytokine\/chemokine profiles of severe acute respiratory syndrome","volume":"171","author":"Jiang","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0330","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMra1608077","article-title":"Acute Respiratory Distress Syndrome","volume":"377","author":"Thompson","year":"2017","journal-title":"New England J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.055_b0335","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1128\/JVI.79.12.7819-7826.2005","article-title":"Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis","volume":"79","author":"Cheung","year":"2005","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0340","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2004-10-4166","article-title":"Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells","volume":"106","author":"Law","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0345","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2021.01.055_b0350","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J General Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0355","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/JVI.03496-12","article-title":"Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus","volume":"87","author":"Zielecki","year":"2013","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0360","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jit504","article-title":"Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis","volume":"209","author":"Zhou","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.055_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155151","article-title":"COVID-19 cytokine storm: The anger of inflammation","volume":"133","author":"Mahmudpour","year":"2020","journal-title":"Cytokine"},{"issue":"23","key":"10.1016\/j.vaccine.2021.01.055_b0370","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.01.055_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030525","article-title":"Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants","volume":"3","author":"Deming","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JVI.01805-10","article-title":"Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus","volume":"85","author":"Sheahan","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0385","doi-asserted-by":"crossref","unstructured":"Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol (Baltimore, Md: 1950) 2008;181(9):6337-48.","DOI":"10.4049\/jimmunol.181.9.6337"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0390","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"issue":"9653","key":"10.1016\/j.vaccine.2021.01.055_b0395","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0400","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.055_b0405","doi-asserted-by":"crossref","unstructured":"Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the medical research council by the measles vaccines committee. Brit Med J 1968;2(5603):449-52.","DOI":"10.1136\/bmj.2.5603.449"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0410","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Reports"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.055_b0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.vaccine.2021.01.055_b0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biologicals.2020.06.005","article-title":"SARS-CoV-2: Virology, epidemiology, immunology and vaccine development","volume":"66","author":"Baay","year":"2020","journal-title":"Biol: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2021.01.055_b0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","article-title":"Towards an evidence based approach for the development of adjuvanted vaccines","volume":"47","author":"O\u2019Hagan","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Human Vaccines Immunotherap"},{"key":"10.1016\/j.vaccine.2021.01.055_b0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2021.01.055_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.06.006","article-title":"Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants","volume":"47","author":"Thompson","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0445","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2011.12.048","article-title":"The concept of vaccination failure","volume":"30","author":"Heininger","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.01.055_b0450","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.2033","article-title":"Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19","author":"Liang","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2021.01.055_b0455","doi-asserted-by":"crossref","unstructured":"Force* TADT. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012;307(23):2526-33.","DOI":"10.1001\/jama.2012.5669"},{"key":"10.1016\/j.vaccine.2021.01.055_b0460","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-015-0191-6","article-title":"Biomarkers of severe dengue disease - a review","volume":"22","author":"John","year":"2015","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/tra.12012","article-title":"Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans","volume":"14","author":"Flipse","year":"2013","journal-title":"Traffic (Copenhagen, Denmark)"},{"issue":"11","key":"10.1016\/j.vaccine.2021.01.055_b0470","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1128\/JVI.00464-14","article-title":"Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy","volume":"88","author":"Walsh","year":"2014","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0475","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1148\/radiol.2020200642","article-title":"Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases","volume":"296","author":"Ai","year":"2020","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0480","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0485","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1007\/s00330-020-06854-1","article-title":"CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city","volume":"30","author":"Zhang","year":"2020","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0490","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1148\/radiol.2020201365","article-title":"The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society","volume":"296","author":"Rubin","year":"2020","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.055_b0495","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/CCM.0b013e31819def97","article-title":"The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation","volume":"37","author":"Jones","year":"2009","journal-title":"Crit Care Med"},{"issue":"10229","key":"10.1016\/j.vaccine.2021.01.055_b0500","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"14","key":"10.1016\/j.vaccine.2021.01.055_b0505","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome in critically ill patients","volume":"286","author":"Ferreira","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0510","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0515","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.cmi.2020.04.012","article-title":"Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect: Off Publ Europ Soc Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0520","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7748\/paed.17.1.32.s27","article-title":"Detecting and managing deterioration in children","volume":"17","author":"Monaghan","year":"2005","journal-title":"Paediatric Nursing"},{"key":"10.1016\/j.vaccine.2021.01.055_b0525","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.resuscitation.2016.07.230","article-title":"Systematic review of paediatric track and trigger systems for hospitalised children","volume":"109","author":"Chapman","year":"2016","journal-title":"Resuscitation"},{"issue":"6","key":"10.1016\/j.vaccine.2021.01.055_b0530","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/archdischild-2016-311088","article-title":"'The Score Matters': wide variations in predictive performance of 18 paediatric track and trigger systems","volume":"102","author":"Chapman","year":"2017","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0535","doi-asserted-by":"crossref","first-page":"R184","DOI":"10.1186\/cc10337","article-title":"Multicentre validation of the bedside paediatric early warning system score: a severity of illness score to detect evolving critical illness in hospitalised children","volume":"15","author":"Parshuram","year":"2011","journal-title":"Critical Care (London, England)"},{"key":"10.1016\/j.vaccine.2021.01.055_b0540","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13063-015-0712-3","article-title":"Evaluating processes of care and outcomes of children in hospital (EPOCH): study protocol for a randomized controlled trial","volume":"16","author":"Parshuram","year":"2015","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2021.01.055_b0545","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12873-019-0287-5","article-title":"Implementation study of a 5-component pediatric early warning system (PEWS) in an emergency department in British Columbia, Canada, to inform provincial scale up","volume":"19","author":"McElroy","year":"2019","journal-title":"BMC Emergency Med"},{"key":"10.1016\/j.vaccine.2021.01.055_b0550","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fonc.2020.00354","article-title":"Abnormal Vital Signs Predict Critical Deterioration in Hospitalized Pediatric Hematology-Oncology and Post-hematopoietic Cell Transplant Patients","volume":"10","author":"Agulnik","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.01.055_b0555","first-page":"996","article-title":"[Nested case-control study on paediatric early warning score and ventilator-associated complications in children with acute respiratory distress syndrome]. Zhong nan da xue xue bao Yi xue ban =","volume":"44","author":"Lu","year":"2019","journal-title":"J Central South Univ Med Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2021.01.055_b0560","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/00003246-198811000-00006","article-title":"Pediatric risk of mortality (PRISM) score","volume":"16","author":"Pollack","year":"1988","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.055_b0565","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.anpede.2019.11.001","article-title":"Paediatric sequential organ failure assessment (pSOFA) score: a new mortality prediction score in the paediatric intensive care unit","volume":"92","author":"El-Mashad","year":"2020","journal-title":"Anales de Pediatr\u00eda (English Edition)"},{"issue":"5","key":"10.1016\/j.vaccine.2021.01.055_b0570","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/PCC.0b013e3181a64be1","article-title":"Day 1 multiple organ dysfunction syndrome is associated with poor functional outcome and mortality in the pediatric intensive care unit","volume":"10","author":"Typpo","year":"2009","journal-title":"Pediatr Crit Care Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0575","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00003246-198604000-00002","article-title":"Outcome of pediatric patients with multiple organ system failure","volume":"14","author":"Wilkinson","year":"1986","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.vaccine.2021.01.055_b0580","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0272989X9901900408","article-title":"Development of a Pediatric Multiple Organ Dysfunction Score: Use of Two Strategies","volume":"19","author":"Leteurtre","year":"1999","journal-title":"Med Decis Making"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0585","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/CCM.0b013e31828a2bbd","article-title":"PELOD-2: an update of the PEdiatric logistic organ dysfunction score","volume":"41","author":"Leteurtre","year":"2013","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0590","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00134-017-5021-8","article-title":"Prognostic accuracy of age-adapted SOFA, SIRS, PELOD-2, and qSOFA for in-hospital mortality among children with suspected infection admitted to the intensive care unit","volume":"44","author":"Schlapbach","year":"2018","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0595","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/01.CCM.0000170943.23633.47","article-title":"The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children","volume":"33","author":"Graciano","year":"2005","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.01.055_b0600","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.vaccine.2021.01.055_b0605","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.vaccine.2021.01.055_b0610","doi-asserted-by":"crossref","first-page":"e172352","DOI":"10.1001\/jamapediatrics.2017.2352","article-title":"Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the sepsis-3 definitions in critically ill children","volume":"171","author":"Matics","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0615","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00134-002-1601-2","article-title":"PIM2: a revised version of the Paediatric Index of Mortality","volume":"29","author":"Slater","year":"2003","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.vaccine.2021.01.055_b0620","first-page":"135","article-title":"Pediatric Logistic Organ Dysfunction-2 (Pelod-2) score as a model for predicting mortality in pediatric burn injury","volume":"32","author":"Dewi","year":"2019","journal-title":"Ann Burns Fire Disasters"},{"key":"10.1016\/j.vaccine.2021.01.055_b0625","doi-asserted-by":"crossref","unstructured":"Watson RS, Crow SS, Hartman ME, Lacroix J, Odetola FO. Epidemiology and Outcomes of Pediatric Multiple Organ Dysfunction Syndrome. Pediatric Crit Care Med: J Soc Crit Care Med World Federat Pediatric Intensive Crit Care Soc 2017;18(3_suppl Suppl 1):S4-S16.","DOI":"10.1097\/PCC.0000000000001047"},{"issue":"19","key":"10.1016\/j.vaccine.2021.01.055_b0630","doi-asserted-by":"crossref","first-page":"502","DOI":"10.21037\/atm.2019.09.31","article-title":"Definition and global epidemiology of pediatric acute respiratory distress syndrome","volume":"7","author":"Beltramo","year":"2019","journal-title":"Ann Trans Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.01.055_b0635","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J Pharmacol Pharmacotherap"},{"key":"10.1016\/j.vaccine.2021.01.055_b0640","unstructured":"The Council for International Organizations of Medical Sciences. CIOMS I FORM; 2020 [Available from: https:\/\/cioms.ch\/cioms-i-form\/]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:46Z","timestamp":1759402726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":128,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X21000943"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}